Conditions: Pulmonary Disease, Chronic Obstructive
Keywords: COPD Safety FEV1 Efficacy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1626
Healthy volunteers: no

Brief summary:
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)

Detailed description:

Arms:
arm 1: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 2: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 3: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) arm 4: Long Acting Beta Agonist(LABA)

Interventions: intervention 1: FF/GW642444 Inhalation Powder intervention 2: GW642444 Inhalation Powder
Intervention descriptions: intervention 1: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD intervention 2: Long Acting Beta Agonist(LABA) Inhalation Powder via DPI

Protocol document: